Recent Articles
The Hype Will Continue to Fade for Ocugen Stock
OCGN stock is pitched as a combination vaccine and biotech play. But the story isn't enough to support a valuation still well past $1 billion.
Social Capital Hedosophia V Stock Is an Easy Buy on the Pullback
IPOE stock has sank largely due to external factors. But SoFi's potential is what matters, and investors can own that growth story at a now-better price.
Affirm Holdings Stock Is a Screaming Buy on the Pullback
Better yet, after its recent correction, shares have fallen to a much more optimal entry point. So, what's the play here? Take advantage of the pullback, and pounce on AFRM stock.
Here’s Your Second Chance… Don’t Let This Mistake Cost You Millions
Altcoins may be intimidating if you're not used to them, but doing a little extra work to learn about them now could net you big returns.
My Top 8 Investment Trends for 2021
The latest MoneyLine podcast digs into eight exciting trends for the rest of 2021 -- and a whole lot longer.
Join Louis Navellier’s Market 360 — FREE!
Get Louis Navellier’s take on the news and events impacting the market, plus his top stock picks.
